# Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

> **NCT06428487** · PHASE2 · COMPLETED · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 30 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Prolgolimab

## Key facts

- **NCT ID:** NCT06428487
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06428487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06428487, "Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06428487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*